SEARCH

SEARCH BY CITATION

Keywords:

  • astrocytoma;
  • glioma;
  • adenovirus;
  • receptor;
  • hCAR;
  • xenograft

Abstract

  1. Top of page
  2. Abstract
  3. MATERIAL AND METHODS
  4. RESULTS
  5. DISCUSSION
  6. Acknowledgements
  7. REFERENCES

The sensitivity of human tissues and tumors to infection with type C adenoviruses correlates with the expression of the human coxsackie B- and adenovirus receptor, hCAR. HCAR is heterogeneously expressed in various tissues and types of human cancer cells, which has implications for the use of adenoviruses as vectors in cancer gene therapy. Using immunoblotting, real-time PCR, FACS-analysis and sensitivity to infection with adenovirus-lacZ, we analyzed the expression level of hCAR in glioma Grade IV cell lines. With real-time PCR, we also analyzed hCAR expression in primary human astrocytomas of different malignancy grades, as well as in their xenograft derivatives. Analysis of a set of 10 cell lines showed great variation in hCAR expression. Susceptibility to Ad5lacZ correlated well with hCAR expression, whereas no correlation was observed with the expression of αvβ3/αvβ5 integrins, proposed to function as co-receptors for adenoviruses. A great variation of CAR expression was also observed in primary astrocytomas of different malignancy grades. The mean value of CAR expression was significantly lower in 22 Grade IV tumors as compared to the values for 6 Grade II (p = 0.01) and 6 Grade III (p = 0.01) tumors. When the hCAR expression in 11 xenografts derived from Grade IV gliomas were compared to the levels detected in the original parental tumors, a mean 12-fold higher expression was seen in the xenografts (P = 0.01). Two xenografts with low hCAR expression grew considerably faster than the hCAR-expressing cells. Our results have relevance for the use of adenoviruses in gene therapy against astrocytomas. © 2002 Wiley-Liss, Inc.

High-grade malignant astrocytomas (anaplastic astrocytomas and glioblastoma multiforme) belong to the group of human cancers with poor prognosis. Because traditional treatment modalities such as surgery, chemotherapy and radiation therapy only marginally affect survival, there is a great need for new alternative therapeutic strategies.1, 2 Based on the local, non-metastatic growth pattern of gliomas, gene therapy has been considered as a possible new approach for the treatment of these tumors. Vector systems used in gene therapy for gliomas include replication-defective retroviruses, adenoviruses (Ad), herpes simplex viruses (HSV) and hybrid vectors derived from them.3, 4, 5, 6, 7, 8, 9, 10 These vectors have been used to deliver a therapeutic (suicide) gene expressing e.g., the herpes simplex virus thymidine kinase (HSVtk) followed by treatment of the patient with ganciclovir. To be useful as an alternative or a complement to traditional treatments, however, better vector systems are needed to achieve a more efficient delivery of the transgenes into the tumor cells.3, 6, 8, 9, 10 This is also true for suicide gene therapy, where transgenes, such as HSVtk, are used and where a bystander effect is obtained.8, 9, 10, 11, 12

Replication-defective recombinant adenoviruses are the most widely used vectors for experimental in vivo cancer gene therapy applications. This is mainly due to their potential to infect a broad range of dividing and non-dividing cells and because they can be produced in large quantities and to high titers.10, 12, 13 In cancer gene therapy trials, adenovirus vectors have been used to deliver therapeutic genes that can act to directly or indirectly, kill or block the growth of the tumor cells, inhibit angiogenesis, stimulate immune responses to tumor antigens or block tumor cell invasion.12, 13 In addition, replicating, tumor cell-selective, oncolytic adenoviruses have been explored as toxic agents.14 Adenovirus Type 2 and 5, the serotypes so far most commonly used in gene therapy, utilize the knob domain of the fiber to bind to its cellular receptor, CAR.15, 16 Upon virus attachment to CAR, viral internalization by endocytosis appears to be facilitated by αvβ3 and αvβ5 integrins.17 CAR is a 46 kDa glycoprotein composed of an extracellular part containing 2 Ig-like domains, a transmembrane region and a cytoplasmic tail.15, 16 Structural analysis has revealed that the Ad fiber knob interacts with the N-terminal Ig domain of the receptor.18, 19 CAR belongs to the CTX-group within the immunoglobulin superfamily20 and seems to be expressed in many different tissues.16, 21, 22, 23

In human tumors and tumor cell lines, CAR expression at quite variable levels has been detected.24, 25, 26, 27, 28, 29, 30 Tumor cells lacking or expressing low levels of CAR are resistant to adenovirus infection and to efficient oncolysis by replicating Ad.31 This has led to new approaches such as tumor targeting, using modifications of the fiber knob to direct the attachment of Ad to cell surface molecules other than CAR.25, 26, 32, 33, 34, 35, 36, 37

The malignant progression from low-grade astrocytomas to high-grade glioblastomas is accompanied by an increasing number of genetic and epigenetic abnormalities.38 Many of these abnormalities center around genes/proteins playing critical roles in the regulation of the cell cycle. Lowered or lost expression of tumor suppressors or increased activity of oncoproteins, both results in cell cycle disturbances and increased proliferation rates.

We have used a standardized quantitative real-time RT-PCR method complemented with other techniques to analyze CAR expression in glioma cell lines, primary tumors and xenografts grown subcutaneously in nude mice.

MATERIAL AND METHODS

  1. Top of page
  2. Abstract
  3. MATERIAL AND METHODS
  4. RESULTS
  5. DISCUSSION
  6. Acknowledgements
  7. REFERENCES

Cell lines

The human glioma cell lines U251MG, U373MG, T98G, A172, U118MG, U87MG, U138MG, TP365MG, TP483MG and H4 were originally established from tumors classified as glioblastoma multiforme (malignancy Grade IV). Their sources have been described previously.39 Normal human foreskin BJ-1 fibroblasts were kindly provided by Dr. Jerry Shay, Department of Cell Biology, University of Texas, Dallas, Texas. HeLa cells and human embryonic kidney (HEK) 293 cells were obtained from American Type Culture Collection (ATCC). All cell lines were grown in DMEM (Life Technologies Inc., Renfrewshire, Scotland) supplemented with 10% FCS (Life Technologies) and 1% each of penicillin, streptomycin and L-glutamine during culturing and experimental procedures.

Tumor material and xenografts

Tumor tissue and non-tumor tissue removed at surgery for brain tumors was collected as described.40 All tumors were classified according to the WHO classification of tumors of the central nervous system.41 The xenografts were generated directly upon surgical removal, by subcutaneous transplantation to the flanks of female nude mice of the Balb/C background (nu/nu, Balb/c, Harlan Sprague-Dawley, Indianapolis, IN).42 The studies were approved by the regional ethical committee for animal experimentation (N229/96) and the human research ethical committees of the Karolinska and Addenbrooke's Hospitals.

Immunofluorescence

Cells to be analyzed by immunofluorescence were plated on coverslips in 6-well plates, grown to 60–70% confluency and fixed for 20 min in 3% paraformaldehyde. After fixation, cells were incubated with the monoclonal antibody, Rmcb 43, washed with PBS and incubated with a secondary TRITC-conjugated anti-mouse IgG (whole molecule (Sigma Immunochemicals, St. Louis, MO). Coverslips were mounted onto slides and photographed with an Axiophot microscope (Zeiss), equipped for immunofluorescence.

Adenovirus infections and counting of β-galactosidase positive cells

The recombinant virus Ad5CMVlacZ was obtained from Quantum Biotechnologies Inc. (USA) and was amplified and purified under standard conditions. The virus titer was determined by plaque assay in 293 cells. To study the susceptibility to adenovirus infection of the different cell lines, 1 × 106 cells of each cell line were seeded onto 6-well plates. The following day, adenovirus was adsorbed onto cells in serum-free medium for 60 min at 37°C, with a multiplicity of infection (MOI) of 10 or 50 pfu/ml. The virus-containing serum-free medium was then replaced by normal growth medium and cells were incubated for another 24 hr at 37°C. Staining with the X-gal substrate was then carried out and positive cells were counted at low magnification in five different optical fields, using a Nikon TMS light microscope.

Immunoblotting

For immunoblotting analysis, cells were lysed in solubilization buffer (1% Triton Tx-100, 20 mM Tris-HCL pH 8.0, 150 mM NaCl, 5 mM EDTA pH 8.0, 100 kIE/ml aprotinin (Trasylol, Bayer AG, Germany). After the removal of cell nuclei by centrifugation, protein concentrations were measured and equal amounts of protein from each cell lysate were loaded onto a 12.5% SDS-PAGE. Proteins were blotted onto nitrocellulose membranes (Hybond ECL, Amersham Life Science), which were incubated with either the mouse, Rmcb, monoclonal antibody (for detection of CAR in the cell lines, Fig. 3b) or a rabbit antibody to the IG1 domain of the receptor (for detection of CAR in the xenografts, Fig. 6b). A rabbit polyclonal antiserum against the endoplasmic reticulum protein, calnexin,44 was used as an internal standard. After washing steps, the membranes were further incubated with secondary anti-mouse or anti-rabbit IgG conjugated to horseradish peroxidase (Amersham) for detection of CAR and calnexin, respectively. Enhanced chemiluminescence (ECL) was carried out under standard conditions. Chemiluminescent signals were quantified using the LAS1000 system (Fuji Photo Film Co. Ltd., Japan) and the ratio between CAR and calnexin expression levels was calculated for each cell lysate.

thumbnail image

Figure 3. Correlation between adenovirus susceptibility and cell surface expression of CAR, αvβ3 and αvβ5 in human glioma cells. (a) The susceptibility to infection of 10 different glioma cell lines was determined by counting the percentage of β-gal positive cells 24 hr post-infection (PI). The results were compared to both hCAR protein and mRNA expression levels, detected by semiquantitative immunoblotting and real-time RT-PCR, respectively. (b) The immunoblot that was used for the quantification of hCAR protein expression levels in the cell lines is shown. (c) Monoclonal antibodies to CAR, αvβ3 or αvβ5 were used in FACS analysis to verify expression of these cell surface proteins on the different cell lines. All incubations were carried out at +4°C and quantification of cells that were gated positive for the different proteins was carried out.

Download figure to PowerPoint

thumbnail image

Figure 6. Expression of hCAR in xenografts from primary glioblastomas. Pieces of excised tumor tissue from patients with diagnosed glioblastoma multiforme were directly transplanted subcutaneously to the flanks of female nude mice with a Balb/C background. After serial passages, total RNA was extracted and quantitative RT-PCR was used to quantify the levels of hCAR expression in the xenografts. (a) The expression levels were compared to those found in the original parental tumor. In the graph, the xenografts and the corresponding parental tumors are presented as 11 matching pairs. (b) An immunoblot showing the expression of hCAR, at the protein level, in 5 selected xenografts and in 4 normal brain samples. *Sample taken from a normal part of the brain of an individual with brain tumor.

Download figure to PowerPoint

FACS analysis

The surface expression of CAR and the integrins αvβ3 and αvβ5 on different cell lines was analyzed by FACS. Cells grown as monolayers were detached by treatment with 10 mM EDTA in phosphate buffered saline (PBS), washed and incubated with monoclonal antibodies against CAR (Rmcb), αvβ3 (clone 23C6, Pharmingen, San Diego, CA) or αvβ5 (clone P1F6, Life Technologies) for 60 min at 4°C. After washing and centrifugation steps, cells were incubated for 30 min at 4°C with FITC-conjugated goat anti-mouse immunoglobulins (F(ab′)2 fragment, DAKO A/S, Denmark) and washed before cytofluorometric analysis. Cells were analyzed on a FACScaliber flow cytometer and CELLQUEST software version 3.1f (both from BD Biosciences-Life Science Research, San Jose, CA).

RNA extraction

Human glioma samples were obtained directly after surgical removal. Total RNA was isolated as described previously.45 Each tumor piece was histologically examined; the majority of specimens contained around 90% tumor cells. Total RNA was treated with RNase free DNase I (Roche) to remove any contaminating genomic DNA. Three micrograms of genomic DNA-free total RNA from each sample was used for cDNA synthesis (100 μl) using SuperScript II RT (GIBCO ERL).

Real Time quantitative PCR

Real Time quantitative PCR was carried out on the LightCycler (Roche) using DNA master SYBR Green I (Roche Molecular Biochemicals) according to the manufacture's protocol. PCR fragments from each target gene were cloned and used at known concentrations to establish standard curves. In each reaction 1 μl of cDNA was used to determine the copy number of the target gene transcript. Each assay was carried out in duplicate. Additionally, the 18S transcript level was used to normalize the cDNA concentration for each sample. The relative expression level of each gene transcript in the tumor samples was compared to normal brain.

Statistical analysis

Because of the non-normal distribution of the samples and the small size of some subsets of tumors, the statistical evaluation was carried out using nonparametric tests. Comparison of the levels of hCAR mRNA expression, detected by real-time RT-PCR, in the different groups of tumors and xenografts was carried out using the Mann-Whitney U-test.

RESULTS

  1. Top of page
  2. Abstract
  3. MATERIAL AND METHODS
  4. RESULTS
  5. DISCUSSION
  6. Acknowledgements
  7. REFERENCES

Correlation between hCAR expression and susceptibility to adenoviruses in glioma cell lines

To correlate CAR expression with sensitivity to infection with adenovirus Type 5, we determined the level of CAR expression in a panel of 10 glioma cell lines using immunoblotting, immunofluorescence and FACS analysis. The cell lines also allowed us to standardize the real-time RT-PCR method for the subsequent quantification of CAR expression in primary astrocytomas. Because HEK293 cells are known to express high levels of hCAR and are easily infected by adenoviruses, this cell line served as a positive control. Human foreskin BJ-1 fibroblasts, based on PCR analysis, expressed undetectable levels of CAR, were included as a negative control. When stained with the monoclonal antibody Rmcb, non-permeabilized 293 cells were clearly positive, displaying a punctate surface staining (Fig. 1a). In contrast, BJ-1 cells were completely negative (Fig. 1f). Representative CAR-positive and -negative glioma cell lines (see below) are shown in Figure 1be. U251MG and U373MG cells clearly stained positive for the receptor (Fig. 1b,c), whereas very low or no staining was observed on T98G and Tp365MG cells (Fig. 1d,e).

thumbnail image

Figure 1. Cell surface expression of CAR in human glioma cell lines. Cells from different cell lines were plated in 6-well plates, grown to 60–70% confluency, fixed with 3% paraformaldehyde without permeabilization and stained with the mouse monoclonal antibody, Rmcb, against CAR. To detect CAR at the cell surface of these cell lines indirect immunofluorescence was carried out, using a secondary TRITC-conjugated goat anti-mouse whole IgG antibody. The different cell lines tested were; (a) 293; (b) U251MG; (c) U373MG; (d) T98G; (e) Tp365MG; (f) BJ-1.

Download figure to PowerPoint

To correlate hCAR expression with susceptibility to adenovirus infectability, the cell lines were infected with recombinant adenoviruses infection either β-galactosidase (Ad5lacZ) or green fluorescent protein (Ad5GFP). As shown in Figure 2, the cell lines expressing levels of hCAR detectable by immunofluorescence were easily transduced with Ad5lacZ (Fig. 2ac), whereas CAR-negative cells could not be infected with the virus (Fig. 2df). Similar results were obtained when Ad5GFP were used to infect the cell lines (data not shown).

thumbnail image

Figure 2. Sensitivity of glioma cell lines to adenovirus infection. The cell lines used in Figure 1 for CAR immunofluorescence staining were infected with the recombinant adenovirus Ad5lacZ at a MOI of 50 pfu/ml. Twenty-four hours later, cells were stained with X-gal and examined for β-galactosidase activity using a Nikon TMS light microscope. (a) 293; (b) U251MG; (c) U373MG; (d) T98G; (e) Tp365MG; (f) BJ-1.

Download figure to PowerPoint

Because we were not able to reliably quantify hCAR protein expression in primary tumors, we used the glioma cell lines to standardize the quantitative real-time RT-PCR method and to evaluate the quality of the data. CAR expression in the 10 cell lines was first studied by immunoblotting (Fig. 3a,b). Two cell lines (U251MG, U373MG) showed high, 2 (A172, H4) low to intermediate and 6 (TP336MG, TP365MG, T98G, U118MG, U87G, U138MG) no, to barely detectable levels of CAR expression.

The relative protein expression levels were then correlated with those of the mRNA by quantitative real-time RT-PCR. In general, the relative protein and mRNA levels in the different glioma cell lines correlated well with each other (Fig. 3a).

Finally, we analyzed the sensitivity of the 10 cell lines to infection by Ad5lacZ by counting the fraction of β-galactosidase-positive cells, 24 hr after infection. Using a multiplicity of infection (MOI) of 50 pfu/cell, the different glioma cell lines were very heterogeneously infected (Fig. 3a). U251MG and U373MG cells were the most easily infected ones, displaying about 90% positive cells. The six CAR-negative cell lines were resistant to adenovirus infection at this MOI, whereas A172 and H4 were partially sensitive, showing about 30–40% positive cells. Thus, there was a good correlation between CAR expression and sensitivity to adenovirus infection.

Expression of αvβ3/αvβ5 integrins in glioma cell lines does not correlate with susceptibility to adenovirus infection

Because it has been shown that αvβ3/αvβ5 integrins can serve as a co-receptor for adenovirus 5 entry into cells,17, 46 we determined the expression of CAR and the integrins of 5 of the cell lines by FACS analysis using the corresponding antibodies. HeLa and 293 cells served as positive controls. As shown in Figure 3c, the expression of αvβ3 was low and variable in the 5 cell lines, whereas all cell lines were clearly positive for αvβ5. Notably, 3 of the cell lines (TP336MG, TP365MG and T98G) that were resistant to adenovirus infection expressed significant amounts of αvβ5. In regard to CAR expression, the results from the FACS analysis correlated well with those from the immunoblotting and RT-PCR analyses.

Quantitative measurement of hCAR mRNA levels in primary astrocytomas

Having standardized the quantitative real-time RT-PCR method using the cell lines, we next analyzed hCAR expression in primary astrocytic tumors. Six low-grade astrocytomas (AII), 6 anaplastic astrocytomas (AAIII) and 22 glioblastomas (GB) were included in the study (Fig. 4). CAR expression varied substantially within each group and between groups. Among the Grade II and III astrocytomas, expression ranged from almost undetectable (A27, AA51) to high (AA93) or very high (A9). With few exceptions, the Grade IV tumors expressed undetectable to low levels of CAR. Statistical analyses indicated that the relative mean expression level of hCAR was significantly lower in the Grade IV tumors (GB) as compared to Grade II (A; p = 0.01) and to Grade III (AA; p = 0.01) tumors (Fig. 5). For comparison, 7 normal human tissues were also included in the study (Fig. 4). High expression of hCAR was detected in kidney and adrenal gland, intermediate levels in small intestine and low, but detectable levels in testis. No or very low expression was found in cerebellum, liver and pancreas. The relative expression level of each tumor and normal sample was compared to the mean value of 10 normal brain samples.

thumbnail image

Figure 4. CAR expression in primary human astrocytomas. Real-time quantitative RT-PCR was carried out to detect hCAR expression in 6 astrocytomas (A, Grade II), 6 anaplastic astrocytomas (AA, Grade III) and 21 glioblastomas (GB, Grade IV). The relative expression level of hCAR mRNA in the tumor samples and in 7 samples from different normal human tissues was compared to normal brain. *The normal brain value represents the mean value of 10 normal brain samples.

Download figure to PowerPoint

thumbnail image

Figure 5. A comparison of hCAR expression levels in Grade II, III and IV astrocytomas. The expression levels were determined by real-time RT-PCR and is presented as a comparison of the mean values ± SEM of the GB:s vs. the A:s or the AA:s. ** p ≤ 0.01 for both analyses.

Download figure to PowerPoint

HCAR mRNA expression in tumor xenografts

Eleven matched pairs of xenografts/glioblastomas were analyzed for hCAR expression by real-time PCR. The results showed a strongly elevated level of hCAR expression in 2 of 11 xenografts as compared to the matching primary tumor tissues (Fig. 6). In these 2 xenografts, A925 and A907, the levels of hCAR were 170 and 230 times higher than in the primary tumors, respectively. In 4 of the 11 xenografts; A894, A1024, A923 and A1174, hCAR expression was 12–42 times higher and in 3 cases, A940, A1222 and A1043, the levels were elevated 2–4 times. Two of the 11 xenografts (A830 and A948) displayed no difference in CAR expression. In total, the calculated mean expression levels were 12-fold higher in the xenografts compared to the tumors (p = 0.01, Fig. 7). The mean induction level for all 11 matched pairs was 46-fold. Immunoblotting analysis, using a rabbit polyclonal antibody against the IG1 domain of CAR, on 5 of the xenografts showed an excellent correlation between the expression of hCAR at the mRNA and protein levels in the different samples (Fig. 6b). Four normal brain samples were also analyzed and were, in agreement with the results obtained from the real-time PCR analysis, found to not express hCAR (Fig. 6b).

thumbnail image

Figure 7. Graphic representation of the upregulation in hCAR expression detected in the xenografts as compared to that in the parental primary glioblastomas. The results are presented as the mean ± SEM.

Download figure to PowerPoint

When comparing glioblastomas that grew as subcutaneous xenografts in nude mice with those that did not grow, no statistically significant difference in hCAR expression levels were seen (Fig. 4).

We finally analyzed whether upregulation of CAR expression correlated with the rate of growth of the xenografts in nude mice. As shown in Table I, the 2 xenografts (A830 and A948) expressing very low levels of CAR grew much faster than the ones with moderate to high CAR expression. These 2 tumors had to be passaged once a month as compared to once every 2–4 months for the others.

Table I. Correlation of hCAR Expression and Proliferation of Xenografts on Nude Mice
XenografthCAR expressionXenograft primary tumorPassaging time (months)
A8300.10.31
A8946.822.73
A90746.7233.53
A92329.241.73
A925121.7173.93
A9405.64.03
A9480.70.91
A10242.512.54.5
A104317.24.23
A11746.015.04
A122227.62.22

DISCUSSION

  1. Top of page
  2. Abstract
  3. MATERIAL AND METHODS
  4. RESULTS
  5. DISCUSSION
  6. Acknowledgements
  7. REFERENCES

Replication-deficient recombinant adenoviruses carrying a therapeutic gene is currently the most frequently employed vector system used in experimental and clinical cancer studies. It is therefore of importance to determine the susceptibility of tumor tissues to adenovirus infection. It has been well documented that the critical determinant for susceptibility to adenovirus infection is the expression of CAR, the primary receptor for adenovirus Type 2 and 5. We have a long standing interest in the characterization of the genetic aberrations and biology of human astrocytic tumors with the aim of improving diagnosis and therapy. In our present study we have analyzed the expression of CAR in a panel of 10 glioblastoma cell lines, a set of 33 primary Grade II–IV astrocytomas and 10 glioblastomas grown as xenografts in nude mice. We found that the level of CAR expression varied markedly between different cell lines as determined by immunoblotting, quantitative PCR and FACS analysis. Sensitivity to adenovirus infection correlated well with the level of CAR expression, whereas no correlation was observed with the expression of the αvβ3/αvβ5 integrins.

Our results are in good agreement with those now obtained for a range of tumor cell lines. The extreme variability of CAR expression levels has been found for e.g., bladder,24 prostate28 and melanoma27 cell lines. In some tumor cell lines, such as rhabdomyosarcoma30 and gastrointestinal cancers,29 CAR expression has been found to be low or undetectable. In regard to glioma cell lines, several groups have documented highly variable levels of CAR expression.25, 47, 48 In our study, we found that 2 of 10 cell lines expressed a high level of CAR, 2 a low to moderate level, whereas 6 were essentially CAR-negative. Some of the cell lines included in our study have also been analyzed previously by other groups. In most cases, the results are in excellent agreement. For the cell line U87MG, however, Mori et al.47 observed a moderate susceptibility to adenovirus infection despite a low level of CAR expression as determined by quantitative PCR. Likewise, Miller et al.,25 observed moderate binding of radiolabeled Ad5 to U87MG and a low level of surface CAR as determined by FACS analysis. In contrast, in the present and a previous49 study, we were unable to detect CAR expression or infect U87MG with a moderate MOI of Ad5. This discrepancy may relate to the passage history of this cell line. Most glioma cell lines have been kept in culture for years or even decades. During such a long history, expression levels of a number of genes may change substantially. In agreement with previous studies25, 29, 47, 48 we found that the susceptibility to adenovirus infection did not correlate with the expression of β3/αvβ5 integrins.

Similarly to the situation in glioma cell lines we found that primary astrocytic tumors also expressed very variable levels of CAR. Glioma Grade II and III showed a statistically significantly higher expression level than glioblastomas (Grade IV). To date there is almost no information in the literature on the expression of CAR protein or mRNA, in primary astrocytic tumors. This is partly due to the inherent problems of reliably quantifying CAR protein expression from tumor tissue. Miller et al.25 demonstrated highly variable susceptibility to adenovirus infection of primary glioma cultures after short-term in vitro culturing. Interestingly, they found that the susceptibility did not correlate with the original histological type of the tumor. Even a few in vitro passages of tumor material may select subsets of cells and result in altered gene expression, however, such as that of CAR. Combined with our results this information should be of importance in regard to clinical trials in which adenovirus vectors are being used for the treatment of glioblastomas.3, 10 From the point of view of practical gene therapy, the expression levels of CAR in the primary tumors is more relevant than that in established cell lines. Future work should thus focus on determining CAR expression in primary tumors and analyzing their susceptibility to adenovirus infection.

The observation that Grade IV tumors expressed lower levels of CAR than the Grade II and III tumors may point to a possible growth advantage for tumors displaying low CAR expression. Alternatively, CAR may be secondarily down-regulated in fast growing cells. The normal cellular function of CAR is not known. Some recent results, however, suggest that CAR may serve as a cell–cell adhesion molecule.50 Other results suggest that CAR expression may inversely correlate with cell growth. Bladder carcinoma cell lines expressing elevated levels of CAR showed increased cell-cell aggregation, displayed a slower growth rate and antibodies to the CAR ectodomain prevented the inhibitory effect of CAR on growth.51 Furthermore, ectopic expression of hCAR in a prostate cancer cell line resulted in a lowered proliferative potential of these cells, both in vitro and in vivo, indicating a tumor suppressive role for CAR.28 Our results also show that absence of CAR expression may contribute to an increased growth rate of glioma cells, because the 2 xenografts displaying no CAR expression grew considerably faster in nude mice than the 9 CAR-positive tumors.

We made the interesting observation that CAR expression in 9 of 11 cases was upregulated in glioblastoma xenografts as compared to their parental, primary tumors. The reason for this is unclear, but may suggest that the gene expression of CAR is induced by factor(s) produced in the mice. So far little is known regarding signaling that leads to regulation of the CAR promoter. Analysis of CAR regulation will have to await a detailed definition of the CAR promoter region and the development of a reporter system for analyzing factors regulating CAR expression.

In conclusion, we have found great variations of CAR expression levels in glioma cell lines and primary astrocytomas of different malignancy grades, as well as xenografts from Grade IV tumors. The implication of these results for adenovirus-mediated gene transfer to patients remains to be investigated. A thorough study correlating CAR levels with susceptibility to adenovirus seems warranted.

Acknowledgements

  1. Top of page
  2. Abstract
  3. MATERIAL AND METHODS
  4. RESULTS
  5. DISCUSSION
  6. Acknowledgements
  7. REFERENCES

We wish to thank A. Bergström for excellent technical assistance.

REFERENCES

  1. Top of page
  2. Abstract
  3. MATERIAL AND METHODS
  4. RESULTS
  5. DISCUSSION
  6. Acknowledgements
  7. REFERENCES
  • 1
    Black PM, Loeffler J. Cancer of the nervous system. Oxford, UK: Blackwell, 1997. 11.
  • 2
    Forsyth PA, Roa WH. Primary central nervous system tumors in adults. Curr Treat Options Neurol 1999; 1: 377394.
  • 3
    Puumalainen AM, Vapalahti M, Agrawal RS, Kossila M, Laukkanen J, Lehtolainen P, Viita H, Paljarvi L, Vanninen R, Yla-Herttuala S. Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. Hum Gene Ther 1998; 9: 176974.
  • 4
    Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 2001; 7: 3340.
  • 5
    Lam PY, Breakefield XO. Hybrid vector designs to control the delivery, fate and expression of transgenes. J Gene Med 2000; 2: 395408.
  • 6
    Gupta N. Current status of viral gene therapy for brain tumors. Expert Opin Investig Drugs 2000; 9: 71326.
  • 7
    Verma I, Somia N. Gene therapy: promises, problems and prospects. Nature 1997; 389: 23942.
  • 8
    Rainov NG. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 2000; 11: 2389401.
  • 9
    Trask T, Trask R, Aguilar-Cordova E, Shine H, Wyde P, Goodman J, Hamilton W, Rojas-Martinez A, Chen S, Woo S, Grossman R. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol Ther 2000; 1: 195203.
  • 10
    Sandmair A, Loimas S, Puranen P, Immonen A, Kossila M, Puranen M, Hurskainen H, Tyynela K, Turunen M, Vanninen R, Lehtolainen P, Paljarvi L, et al. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther 2000; 11: 2197205.
  • 11
    Lam PY, Breakefield XO. Potential of gene therapy for brain tumors. Hum Mol Genet 2001; 10: 77787.
  • 12
    Zhang W. Development and application of adenoviral vectors for gene therapy of cancer. Cancer Gene Ther 1999; 6: 11338.
  • 13
    Benihoud K, Yeh P, Perricaudet M. Adenovirus vectors for gene delivery. Curr Opin Biotechnol 1999; 10: 4407.
  • 14
    Alemany R, Balague C, Curiel DT. Replicative adenoviruses for cancer therapy. Nat Biotechnol 2000; 18: 7237.
  • 15
    Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 13203.
  • 16
    Tomko R, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 1997; 94: 33526.
  • 17
    Wickham T, Mathias P, Cheresh D, Nemerow G. Integrins αv β3 and αv β5 promote adenovirus internalization but not virus attachment. Cell 1993; 73: 30919.
  • 18
    Roelvink PW, Mi L, G, Einfeld DA, Kovesdi I, Wickham TJ. Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing Adenoviridae. Science 1999; 286: 156871.
  • 19
    Bewley MC, Springer K, Zhang YB, Freimuth P, Flanagan JM. Structural analysis of the mechanism of adenovirus binding to its human cellular receptor, CAR. Science 1999; 286: 157983.
  • 20
    Chretien I, Marcuz A, Courtet M, Katevuo K, Vainio O, Heath JK, White SJ, Du P, L. CTX, a Xenopus thymocyte receptor, defines a molecular family conserved throughout vertebrates. Eur J Immunol 1998; 28: 4094104.
  • 21
    Fechner H, Haack A, Wang H, Wang X, Eizema K, Pauschinger M, Schoemaker R, Veghel R, Houtsmuller A, Schultheiss HP, Lamers J, Poller W. Expression of coxsackie adenovirus receptor and αv-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Ther 1999; 6: 152035.
  • 22
    Bergelson JM, Krithivas A, Celi L, Droguett G, Horwitz MS, Wickham T, Crowell RL, Finberg RW. The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses. J Virol 1998; 72: 4159.
  • 23
    Tomko R, Johansson C, Totrov M, Abagyan R, Frisen J, Philipson L. Expression of the adenovirus receptor and its interaction with the fiber knob. Exp Cell Res 2000; 255: 4755.
  • 24
    Li Y, Pong RC, Bergelson JM, Hall MC, Sagalowsky AI, Tseng CP, Wang Z, Hsieh JT. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res 1999; 59: 32530.
  • 25
    Miller CR, Buchsbaum DJ, Reynolds PN, Douglas JT, Gillespie GY, Mayo MS, Raben D, Curiel DT. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res 1998; 58: 573848.
  • 26
    Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G, Belousova N, Curiel DT. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72: 970613.
  • 27
    Hemmi S, Geertsen R, Mezzacasa A, Peter I, Dummer R. The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. Hum Gene Ther 1998; 9: 236373.
  • 28
    Okegawa T, Li Y, Pong RC, Bergelson JM, Zhou J, Hsieh JT. The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy. Cancer Res 2000; 60: 50316.
  • 29
    Fechner H, Wang X, Wang H, Jansen A, Pauschinger M, Scherubl H, Bergelson JM, Schultheiss HP, Poller W. Trans-complementation of vector replication versus Coxsackie-adenovirus-receptor overexpression to improve transgene expression in poorly permissive cancer cells. Gene Ther 2000; 7: 195468.
  • 30
    Cripe TP, Dunphy EJ, Holub AD, Saini A, Vasi NH, Mahller YY, Collins MH, Snyder JD, Krasnykh V, Curiel DT, Wickham TJ, DeGregori J, et al. Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus-adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells. Cancer Res 2001; 61: 295360.
  • 31
    Douglas JT, Kim M, Sumerel LA, Carey DE, Curiel DT. Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors. Cancer Res 2001; 61: 8137.
  • 32
    Hidaka C, Milano E, Leopold PL, Bergelson JM, Hackett NR, Finberg RW, Wickham TJ, Kovesdi I, Roelvink P, Crystal RG. CAR-dependent and CAR-independent pathways of adenovirus vector- mediated gene transfer and expression in human fibroblasts. J Clin Invest 1999; 103: 57987.
  • 33
    Wickham T, Tzeng E, Shears L 2nd, Roelvink P, Li Y, Lee G, Brough D, Lizonova A, Kovesdi I. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol 1997; 71: 82219.
  • 34
    Wickham T. Targeting adenovirus. Gene Ther 2000; 7: 1104.
  • 35
    Vanderkwaak T, Wang M, Gomez-Navarro J, Rancourt C, Dmitriev I, Krasnykh V, Barnes M, Siegal G, Alvarez R, Curiel D. An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches. Gynecol Oncol 1999; 74: 22734.
  • 36
    Reynolds P, Dmitriev I, Curiel D. Insertion of an RGD motif into the HI loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administered vector. Gene Ther 1999; 6: 13369.
  • 37
    Krasnykh VN, Douglas JT, van B, V W. Genetic targeting of adenoviral vectors. Mol Ther 2000; 1: 391405.
  • 38
    Collins VP. Gliomas. Cancer Surv 1998; 32: 3751.
  • 39
    Collins VP. Cultured human glial and glioma cells. Int Rev Exp Pathol 1983; 24: 135202.
  • 40
    Reifenberger G, Reifenberger J, Ichimura K, Meltzer PS, Collins VP. Amplification of multiple genes from chromosomal region 12q13–14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS and MDM2. Cancer Res 1994; 54: 4299303.
  • 41
    Kleihues P, Cavenee WK. Tumours of the nervous system. Lyon: IARC, 1997. 66.
  • 42
    Goike HM, Asplund AC, Pettersson EH, Liu L, Sanoudou D, Collins VP. Acquired rearrangement of an amplified epidermal growth factor receptor (EGFR) gene in a human glioblastoma xenograft. J Neuropathol Exp Neurol 1999; 58: 697701.
  • 43
    Hsu KH, Lonberg-Holm K, Alstein B, Crowell RL. A monoclonal antibody specific for the cellular receptor for the group B coxsackieviruses. J Virol 1988; 62: 164752.
  • 44
    Andersson AM, Pettersson RF. Targeting of a short peptide derived from the cytoplasmic tail of the G1 membrane glycoprotein of Ukuniemi virus (Bunyaviridae) to the Golgi complex. J Virol 1998; 72: 958596.
  • 45
    Ichimura K, Schmidt EE, Goike HM, Collins VP. Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 1996; 13: 106572.
  • 46
    Goldman MJ, Wilson JM. Expression of αv β5 integrin is necessary for efficient adenovirus-mediated gene transfer in the human airway. J Virol 1995; 69: 59518.
  • 47
    Mori T, Arakawa H, Tokino T, Mineura K, Nakamura Y. Significant increase of adenovirus infectivity in glioma cell lines by extracellular domain of hCAR. Oncol Res 1999; 11: 51321.
  • 48
    Asaoka K, Tada M, Sawamura Y, Ikeda J, Abe H. Dependence of efficient adenoviral gene delivery in malignant glioma cells on the expression levels of the Coxsackievirus and adenovirus receptor. J Neurosurg 2000; 92: 10028.
  • 49
    Fuxe J, Akusjarvi G, Goike HM, Roos G, Collins VP, Pettersson RF. Adenovirus-mediated overexpression of p15INK4B inhibits human glioma cell growth, induces replicative senescence and inhibits telomerase activity similarly to p16INK4A. Cell Growth Differ 2000; 11: 37384.
  • 50
    Honda T, Saitoh H, Masuko M, Katagiri-Abe T, Tominaga K, Kozakai I, Kobayashi K, Kumanishi T, Watanabe YG, Odani S, Kuwano R. The coxsackievirus-adenovirus receptor protein as a cell adhesion molecule in the developing mouse brain. Brain Res Mol Brain Res 2000; 77: 1928.
  • 51
    Okegawa T, Pong RC, Li Y, Bergelson JM, Sagalowsky AI, Hsieh JT. The mechanism of the growth-inhibitory effect of coxsackie and adenovirus receptor (CAR) on human bladder cancer: a functional analysis of car protein structure. Cancer Res 2001; 61: 6592600.